Mediaboss Marketing

PRESS RELEASE: Epigenomics AG: Clinical study conducted in the Czech Republic confirms blood-based Septin9 test to be an attractive alternative for CRC screening programs

DGAP-News: Epigenomics AG / Key word(s): Study Epigenomics AG: Clinical study conducted in the Czech Republic confirms blood-based Septin9 test to be an attractive alternative for CRC screening programs

05.03.2014 / 09:00

=--------------------------------------------------------------------

Epigenomics AG: Clinical study conducted in the Czech Republic confirms blood-based Septin9 test to be an attractive alternative for CRC screening programs

- Study conducted using Epigenomics' Epi proColon(R) 2.0 CE

- Results in line with the results achieved in the CE marking study reported in 2011

- Patient convenience might help to increase early colorectal cancer (CRC) detection especially with non-compliant individuals

Berlin (Germany) and Germantown, MD (U.S.A.), March 5, 2014 - Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced findings from a study executed in different centers in Prague, Pilsen, and Brno. According to the study published in "Vnitr Lk", a leading Czech journal for internal medicine, in late 2013 blood-based Septin9 testing could be an attractive screening alternative to established methods for a population that would otherwise be non-compliant to colorectal cancer screening. The study was conducted by MU Dr. Zdenek Bene , CSc., Head, Medical department of Thomayer Hospital, Prague.

The case control study comprised 57 patients; 33 asymptomatic individuals with negative colonoscopies, and 24 patients with proven adenomas. In this study, Epi proColon(R) 2.0 CE showed a sensitivity of 92% and a specificity of 97%. These results are in line with the results achieved in the CE marking study reported in 2011, which followed the same principle of data interpretation (80% sensitivity and 99% specificity).

Read this article:
PRESS RELEASE: Epigenomics AG: Clinical study conducted in the Czech Republic confirms blood-based Septin9 test to be ...